Literature DB >> 8487073

A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study.

H J Eyre1, J J Crowley, J J Townsend, J R Eltringham, R A Morantz, S F Schulman, J M Quagliana, M al-Sarraf.   

Abstract

Sixty adult patients with incompletely excised low-grade gliomas were randomly assigned to receive radiotherapy (55 Gy over a total of 6 1/2 to 7 weeks) either alone or with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; 100 mg/sq m every 6 weeks). Pathological review showed that six patients were ineligible for the study. Evaluation of patient age, extent of surgery, tumor grade, and performance status showed no significant differences between the treatment arms. The response rate, as judged by the disappearance or reduction in size of the tumor on computerized tomography scans, was 79% for radiation therapy alone versus 54% for irradiation plus CCNU. The median survival time was 4.45 years for all patients, with no significant difference between treatment arms (p = 0.7). For the group as a whole, patient age and performance status were the most important prognostic parameters. The majority of patients receiving chemotherapy experienced moderate hematological toxicity. This study demonstrates that CCNU chemotherapy does not improve the results of radiation therapy in the treatment of incompletely excised low-grade gliomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8487073     DOI: 10.3171/jns.1993.78.6.0909

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  37 in total

Review 1.  Radiation therapy for incompletely resected supratentorial low-grade glioma in adults.

Authors:  B Jeremic; M Bamberg
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

2.  The dilemma of low grade glioma.

Authors:  I R Whittle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

3.  Response to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas.

Authors:  Michal Spych; Leszek Gottwald; Emilia Jesień-Lewandowicz; Sławomir Sztajer; Jacek Fijuth
Journal:  Oncol Lett       Date:  2012-06-14       Impact factor: 2.967

4.  [Conventionally fractioned postoperative radiotherapy up to 50.4 Gy for progressive low-grade gliomas in adults still standard treatment].

Authors:  G G Grabenbauer
Journal:  Strahlenther Onkol       Date:  2013-04       Impact factor: 3.621

Review 5.  Radiation therapy and grade II/III oligodendroglial tumors.

Authors:  Caroline Chung; Normand Laperriere
Journal:  CNS Oncol       Date:  2015-10-19

6.  Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.

Authors:  Ali Chahlavi; Andrew Kanner; David Peereboom; Susan M Staugaitis; Paul Elson; Gene Barnett
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

7.  Treatment of low-grade diffuse astrocytomas by surgery and human fibroblast interferon without radiation therapy.

Authors:  Takao Watanabe; Yoichi Katayama; Atsuo Yoshino; Chiaki Komine; Takakazu Yokoyama; Takao Fukushima
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

Review 8.  Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities.

Authors:  Martin Klein
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 9.  Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults.

Authors:  Lynn S Ashby; William R Shapiro
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

Review 10.  Low-grade gliomas.

Authors:  Jimmy Ruiz; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2009-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.